Prognosis
J&J’s Second Act Creates New Challenge for Immunization Effort
- After a pause for safety concerns, U.S. must battle skepticism
- Slowing vaccination campaign creates new obstacles for shot
This article is for subscribers only.
For Americans wary of the Johnson & Johnson Covid-19 vaccine as it returns to use after the investigation of a potentially deadly side effect, health experts have a message: The system worked.
A recommended hold on the vaccine was lifted on Friday by the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration after a 10-day review of rare and serious blood clots in some people who had received the shot.